OLMA vs. CGON, QURE, RARE, APLS, IMVT, GMTX, OGN, MOR, KNSA, and HCM
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Gemini Therapeutics (GMTX), Organon & Co. (OGN), MorphoSys (MOR), Kiniksa Pharmaceuticals International (KNSA), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs. Its Competitors
Olema Pharmaceuticals (NASDAQ:OLMA) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Olema Pharmaceuticals has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 16.4% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 7.4% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Olema Pharmaceuticals currently has a consensus price target of $23.33, indicating a potential upside of 117.05%. CG Oncology has a consensus price target of $58.82, indicating a potential upside of 36.91%. Given Olema Pharmaceuticals' higher probable upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than CG Oncology.
Olema Pharmaceuticals has a net margin of 0.00% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -19.37% beat Olema Pharmaceuticals' return on equity.
CG Oncology has higher revenue and earnings than Olema Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, CG Oncology had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 15 mentions for CG Oncology and 9 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.45 beat CG Oncology's score of 0.41 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Summary
CG Oncology beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 10/13/2025 by MarketBeat.com Staff
